Pacer Advisors
DGX icon

Pacer Advisors’s Quest Diagnostics DGX Stock Holding History

Pacer Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.5M Sell
425,895
-21,832
-5% -$4.24M 0.23% 104
2025
Q4 		$77.7M Sell
447,727
-3,171
-0.7% -$577K 0.2% 113
2025
Q3 		$85.9M Buy
450,898
+433,764
+2,532% +$77M 0.22% 97
2025
Q2 		$3.08M Buy
17,134
+11,426
+200% +$1.98M 0.01% 858
2025
Q1 		$966K Sell
5,708
-3,304
-37% -$543K ﹤0.01% 1223
2024
Q4 		$1.36M Sell
9,012
-25,321
-74% -$3.94M ﹤0.01% 1205
2024
Q3 		$5.33M Buy
34,333
+8,763
+34% +$1.31M 0.01% 638
2024
Q2 		$3.5M Sell
25,570
-2,733
-10% -$374K 0.01% 726
2024
Q1 		$3.77M Sell
28,303
-3,609
-11% -$468K 0.01% 660
2023
Q4 		$4.4M Buy
31,912
+21,327
+201% +$2.8M 0.01% 599
2023
Q3 		$1.29M Sell
10,585
-181
-2% -$24.1K ﹤0.01% 733
2023
Q2 		$1.51M Sell
10,766
-597,176
-98% -$82.3M 0.01% 843
2023
Q1 		$86M Buy
607,942
+74,623
+14% +$10.7M 0.37% 64
2022
Q4 		$83.4M Buy
533,319
+171,663
+47% +$24.7M 0.43% 60
2022
Q3 		$44.4M Sell
361,656
-54,850
-13% -$7.22M 0.31% 66
2022
Q2 		$55.4M Buy
416,506
+148,761
+56% +$20.3M 0.41% 49
2022
Q1 		$36.6M Buy
267,745
+185,520
+226% +$25.9M 0.3% 76
2021
Q4 		$14.2M Buy
82,225
+1,397
+2% +$213K 0.15% 120
2021
Q3 		$11.7M Buy
80,828
+8,588
+12% +$1.26M 0.15% 166
2021
Q2 		$9.53M Buy
72,240
+38,360
+113% +$5.02M 0.14% 143
2021
Q1 		$4.35M Buy
33,880
+6,445
+23% +$794K 0.08% 279
2020
Q4 		$3.27M Buy
27,435
+13,242
+93% +$1.61M 0.06% 313
2020
Q3 		$1.63M Sell
14,193
-1,675
-11% -$198K 0.03% 493
2020
Q2 		$1.81M Buy
+15,868
New +$1.68M 0.04% 400
2020
Q1 		– Sell
-15,158
Closed -$1.62M – 780
2019
Q4 		$1.62M Sell
15,158
-1,662
-10% -$173K 0.07% 357
2019
Q3 		$1.8M Buy
16,820
+1,694
+11% +$174K 0.04% 541
2019
Q2 		$1.54M Buy
15,126
+3,031
+25% +$291K 0.04% 614
2019
Q1 		$1.09M Buy
+12,095
New +$1.05M 0.03% 435
2018
Q4 		– Sell
-7,517
Closed -$811K – 677
2018
Q3 		$811K Buy
7,517
+1,096
+17% +$120K 0.03% 735
2018
Q2 		$706K Buy
6,421
+1,116
+21% +$116K 0.03% 787
2018
Q1 		$532K Buy
5,305
+641
+14% +$65.7K 0.03% 725
2017
Q4 		$459K Buy
4,664
+1,674
+56% +$159K 0.03% 733
2017
Q3 		$280K Buy
2,990
+280
+10% +$29.7K 0.02% 892
2017
Q2 		$301K Buy
2,710
+203
+8% +$21.5K 0.03% 845
2017
Q1 		$246K Buy
2,507
+77
+3% +$7.34K 0.03% 840
2016
Q4 		$223K Sell
2,430
-14
-0.6% -$1.21K 0.03% 818
2016
Q3 		$207K Sell
2,444
-14
-0.6% -$1.18K 0.03% 801
2016
Q2 		$200K Buy
2,458
+36
+1% +$2.74K 0.03% 794
2016
Q1 		$173K Buy
2,422
+133
+6% +$8.92K 0.04% 439
2015
Q4 		$163K Buy
+2,289
New +$154K 0.04% 434

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Pacer Advisors's DGX Position: Q1 2026 in Review

Pacer Advisors reduced its Quest Diagnostics (DGX) stake by 4.9% in Q1 2026, selling an estimated $4.24M and leaving 425,895 shares worth $83.5M. The position accounts for 0.23% of the portfolio, ranked #104.

Pacer Advisors first reported a position in DGX in Q4 2015 and has held it in 40 quarters since. The position peaked at $86M in Q1 2023. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Pacer Advisors held 425,895 shares of Quest Diagnostics worth $83.5M as of Q1 2026.
  • Pacer Advisors sold 21,832 Quest Diagnostics shares in Q1 2026, an estimated $4.24M.
  • Quest Diagnostics made up 0.23% of Pacer Advisors's portfolio in Q1 2026, its #104 holding.
  • Pacer Advisors first reported a position in Quest Diagnostics in Q4 2015 and has held it in 40 quarters since.
  • Pacer Advisors's Quest Diagnostics position peaked at $86M in Q1 2023.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.